Table 1.
Analysis of the correlation between miR-30a-5p expression and clinic-pathologic features in the TCGA LUAD dataset.
| Characteristic | Low expression of hsa-miR-30a-5p | High expression of hsa-miR-30a-5p | p |
|---|---|---|---|
| n | 499 | 500 | |
| T stage, n (%) | < 0.001 | ||
| T1 | 108 (10.8%) | 171 (17.2%) | |
| T2 | 303 (30.4%) | 255 (25.6%) | |
| T3 | 70 (7%) | 48 (4.8%) | |
| T4 | 17 (1.7%) | 24 (2.4%) | |
| N stage, n (%) | 0.008 | ||
| N0 | 296 (30.2%) | 341 (34.8%) | |
| N1 | 128 (13.1%) | 94 (9.6%) | |
| N2 | 66 (6.7%) | 48 (4.9%) | |
| N3 | 3 (0.3%) | 3 (0.3%) | |
| M stage, n (%) | 0.493 | ||
| M0 | 368 (47.8%) | 373 (48.4%) | |
| M1 | 12 (1.6%) | 17 (2.2%) | |
| Age, meidan (IQR) | 66 (59, 72) | 68 (62, 74) | < 0.001 |